Resources

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA’s acceptance of the filing.

Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators.

Senior leaders from PHTA and Clinical Immunology Services took home the top prizes in two prestigious categories at the West Midlands Innovation Awards

In this analysis by Dr Martin Turner, Director of Policy and External Affairs, BIA, discover how the 2025 Budget could supercharge UK life sciences scale-ups with major investment incentives - while also highlighting potential risks from rising business rates.

Cath Green OBE received the Peter Dunnill Award for her exceptional leadership during COVID-19; the Future Targeted Healthcare Manufacturing Hub was awarded the Richard Wilson Impact Award and Emilia Reyes Pabon received the Bioprocessing Apprentice of the Year Award.

The Functional Genomics Screening Laboratory, based at the Milner Therapeutics Institute, has won an OBN Award in the category of Most Impactful Industry Collaboration.

Read our statement welcoming the Chancellor’s extended venture investment tax incentives and support for employee share options, as well as the prioritisation of tax and spending decisions in areas where the UK can lead and win.

From stronger STEM foundations and digital/AI literacy in schools to clearer post-16 technical pathways and lifelong learning opportunities, these reforms offer a once-in-a-generation chance to prepare a workforce ready for the next wave of biotech innovation.

GLP-1 collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability.

In this blog, Lewis Miles, Policy and Public Affairs Manager at the BIA, reflects on an intense period of engagement with Ministers and Parliament ahead of the Autumn Budget.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

In this spotlight feature, Bev Cameron, Sales Director for EMEA & APAC at Aldevron, shares how the company is helping accelerate next-generation genomic medicines, from personalised CRISPR therapies to ready-to-scale platforms that support innovators across the development journey.

London Life Sciences Week was a huge success last week, with significant increase in investors and life sciences execs coming together to connect and network.  Combined with the news of two new significant fund raises from Sofinnova and Medicxi and progress towards completion of the British Growth Partnership Fund, it did feel that the sector found a lot to be hopeful about. 

In this blog, Dr Kate Barclay, Skills Strategy Consultant at BIA, explores two pivotal developments — the National Curriculum review and Skills England’s AI Skills for the UK Workforce report — and what they mean for preparing the next generation of scientifically confident, AI-literate talent for biotech.

In a landscape where efficiency, scalability, and quality are critical, automation is no longer just about doing more; it’s about understanding more. Olivia Dell-Price, Pharmaceutical Automation Specialist at Labman, explores how the future of biomanufacturing is becoming intelligent, connected and data-driven.

AI-powered protein engineering promises speed, precision and scalability - but only if you have the right data. For most teams, that’s the biggest barrier. For ACROBiosystems, it’s a decade-long advantage. Read this blog by Ruiyuan Zheng, Marketing Product Manager, ACROBiosystems, to learn more about how they solved it. 

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Slingshot Therapeutics Limited and is pleased to announce the placement of Dr John Isaac as Chief Scientific Officer.

Constructive Bio and RxCelerate have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases. Combining Constructive Bio’s pioneering programmable biology platform with RxCelerate’s expert drug design and development capabilities to drive innovation in engineered biologics for challenging diseases.

T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising afurther $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.